Plain-English translation of NCT06133972 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is an extension study testing , a new medication designed to help people with systemic lupus erythematosus (lupus) by reducing disease activity. The study involves people who already completed an earlier lupus treatment trial and are now continuing to receive the medication to see how safe and tolerable it is over the long term. Some participants will receive the medication by injection either once a month or once every three months, while others will receive a placebo (inactive injection) to compare how well the treatment works.
Lupus is a serious autoimmune disease that can cause significant harm to the body, and current treatment options are limited. This trial exists to gather long-term safety information about this new treatment to make sure it remains safe and works well when used over extended periods in people living with moderate-to-severe lupus.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive the new medication or placebo by injection under your skin—either once a month or once every three months, depending on which group you are randomly assigned to. You will continue regular study visits to have your blood tested and your lupus symptoms checked, allowing researchers to monitor your safety and how well the treatment is working. The study continues for an extended period to gather comprehensive long-term safety data on this new approach to lupus treatment.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States